庄家控的死死的_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

华仔牛牛
09-12

庄家控的死死的

药捷安康-B日内涨幅扩大逾120%！该股自上市以来累涨逾1600%

9月12日，$药捷安康-B(02617)$盘初再飙逾18%，股价续刷上市以来新高，总市值突破500亿港元。

药捷安康-B日内涨幅扩大逾120%！该股自上市以来累涨逾1600%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":477806073926040,"tweetId":"477806073926040","gmtCreate":1757661391116,"gmtModify":1757661392999,"author":{"id":4105092466274000,"idStr":"4105092466274000","authorId":4105092466274000,"authorIdStr":"4105092466274000","name":"华仔牛牛","avatar":"https://static.tigerbbs.com/a3aeb6958f8a3f90408acd424c9395fe","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.04","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":408,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":408,"starInvestorOrderShareNum":162,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":159.11,"showRor":true,"investmentPhilosophy":"只买自己熟悉的股票。做好人，买好股，得好报。尽量做到每只股票都不亏损。开始学习期权中。","winRationPercentage":80,"tradeVolumeEst":0},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>庄家控的死死的</p></body></html>","htmlText":"<html><head></head><body><p>庄家控的死死的</p></body></html>","text":"庄家控的死死的","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/477806073926040","repostId":1109419271,"repostType":4,"repost":{"id":"1109419271","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1757654231,"share":"https://www.laohu8.com/m/news/1109419271?lang=&edition=full","pubTime":"2025-09-12 13:17","market":"hk","language":"zh","title":"药捷安康-B日内涨幅扩大逾120%！该股自上市以来累涨逾1600%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109419271","media":"老虎资讯综合","summary":"9月12日，$药捷安康-B(02617)$盘初再飙逾18%，股价续刷上市以来新高，总市值突破500亿港元。","content":"<html><head></head><body><p>9月12日，<a href=\"https://laohu8.com/S/02617\">药捷安康-B</a>日内涨幅扩大逾120%，本周累涨逾270%，6月底上市以来累涨逾1600%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/304a5074fc668f176367f2b5728a5999\" tg-width=\"560\" tg-height=\"240\"/></p><p>药捷安康-B近日公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)联合氟维司群治疗经治失败的激素受体阳性(HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已于2025年9月 10日获得了中国国家药品监督管理局的临床默示许可。</p><p style=\"text-align: justify;\">本试验为在中国开展的一项评价替恩戈替尼片联合氟维司群注射液用于经治失败的HR+/HER2-的复发或转移性乳腺癌患者的安全性、疗效及药代动力学的开放标签、多中心、II期临床研究。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药捷安康-B日内涨幅扩大逾120%！该股自上市以来累涨逾1600%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药捷安康-B日内涨幅扩大逾120%！该股自上市以来累涨逾1600%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-09-12 13:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>9月12日，<a href=\"https://laohu8.com/S/02617\">药捷安康-B</a>日内涨幅扩大逾120%，本周累涨逾270%，6月底上市以来累涨逾1600%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/304a5074fc668f176367f2b5728a5999\" tg-width=\"560\" tg-height=\"240\"/></p><p>药捷安康-B近日公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)联合氟维司群治疗经治失败的激素受体阳性(HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已于2025年9月 10日获得了中国国家药品监督管理局的临床默示许可。</p><p style=\"text-align: justify;\">本试验为在中国开展的一项评价替恩戈替尼片联合氟维司群注射液用于经治失败的HR+/HER2-的复发或转移性乳腺癌患者的安全性、疗效及药代动力学的开放标签、多中心、II期临床研究。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","relate_stocks":{"02617":"药捷安康-B"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109419271","content_text":"9月12日，药捷安康-B日内涨幅扩大逾120%，本周累涨逾270%，6月底上市以来累涨逾1600%。药捷安康-B近日公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)联合氟维司群治疗经治失败的激素受体阳性(HR+)且人表皮生长因子受体2阴性或低表达(HER2-)的复发或转移性乳腺癌II期临床试验，已于2025年9月 10日获得了中国国家药品监督管理局的临床默示许可。本试验为在中国开展的一项评价替恩戈替尼片联合氟维司群注射液用于经治失败的HR+/HER2-的复发或转移性乳腺癌患者的安全性、疗效及药代动力学的开放标签、多中心、II期临床研究。","news_type":1,"symbols_score_info":{"02617":1.5}},"isVote":1,"tweetType":1,"viewCount":75,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}